Enzalutamide (Xtandi) approved
Important news from NICE for the 4,100 men each year who are unsuitable for the standard treatment of docetaxel chemotherapy and who have, until now, had limited treatment options (June ’21).  More here:
Important news from NICE for the 4,100 men each year who are unsuitable for the standard treatment of docetaxel chemotherapy and who have, until now, had limited treatment options (June ’21).  More here: